Intuitive Surgical, Inc. vs Morgan Stanley — how do they compare? Intuitive Surgical, Inc. trades at $416 (market cap $146.76B), while Morgan Stanley trades at $188.6 (market cap $294.39B). The key difference: Morgan Stanley is far larger — about 2× Intuitive Surgical, Inc.'s market cap, and Morgan Stanley pays a 2.45% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Morgan Stanley for 93 Days on average.
| ISRG | MS | |
|---|---|---|
Market Cap | $146.76B | $294.39B |
Volume | 2,529,814 | 5,836,423 |
Sector | Health | Financials |
52-Week High | $592.85 | $228.42 |
52-Week Low | $332.02 | $151.86 |
Typical Hold Time | 84 Days | 93 Days |
Enterprise Value | $141.54B | $660.04B |
Dividend Yield | — | 2.45% |
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $414.52, up 2.41% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 2025 revenue reaching $10.06 billion and net income of $2.86 billion, maintaining impressive profit margins above 28%. Recent expansion into ambulatory surgery centers and international markets like India and Japan provides growth catalysts, though China headwinds present challenges. Technical indicators show bullish momentum with support at $411 and resistance at $417.
ISRG presents a compelling growth story with dominant market positioning in robotic surgery and strong recurring revenue streams. The stock offers 16% upside to the consensus price target of $480.78, supported by 70% analyst buy ratings. Key risks include competitive pressures in robotic surgery and international market volatility. The company's consistent earnings outperformance and expanding global footprint suggest continued growth potential despite near-term headwinds.
Morgan Stanley (MS) trades at $187.41, down 1.86% on the day, with a bearish technical signal but strong fundamentals including a P/E of 15.32 and net income margin of 27.59%. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, rising from $50.2B in 2022 to $66.0B in 2025, and the company highlights growth opportunities in wealth management and AI financing.
The outlook is supported by a bullish analyst consensus with a $229.25 price target, though risks include volatile cash flows and rising debt-to-asset ratios. Near-term price action is testing support near $184, with investor sentiment mixed amid fading capital markets momentum but positive long-term growth narratives.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →